URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Edith Lord

TitleProfessor
InstitutionSchool of Medicine and Dentistry
DepartmentMicrobiology and Immunology
AddressUniversity of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 316
Rochester NY 14642
Other Positions
TitleSenior Associate Dean, Graduate Education
InstitutionSchool of Medicine and Dentistry
DepartmentDean's Office M&D - Administration

TitleProfessor
InstitutionUniversity of Rochester Medical Center
DepartmentCancer Center

 
 Overview
Dr. Edith Lord is the Senior Associate Dean for Graduate Education and Postdoctoral Affairs at the School of Medicine and Dentistry. Dr. Lord received her BA degree in microbiology from the University of Kansas in 1970 and a Ph.D degree in immunology from the University of California at San Diego in 1975. She was a postdoctoral fellow at the University of California at San Francisco. Dr. Lord leads the School of Medicine and Dentistry's Ph.D., postdoctoral and master's degree programs. As a faculty member since 1976, Dr. Lord has demonstrated excellence as a scientist and dedication to her position as Senior Associate Dean.

From 2006-2008, Dr. Lord led the graduate program in the Department of Microbiology and Immunology. She also directs the school's Post-baccalaureate Research and Education Program (PREP), which encourages underrepresented minorities to pursue a research doctorate and prepares them for careers as scientists and leaders in the biomedical community.

In her research, Dr. Lord focuses on the immune responses that can control tumor development and also studies the unique microenvironment present within growing tumors. She has published, as author and co-author, more than 100 scientific articles and continues her passion for research today.

 
 Selected Publications
List All   |   Timeline
  1. Xu Y, Hyun YM, Lim K, Lee H, Cummings RJ, Gerber SA, Bae S, Cho TY, Lord EM, Kim M. Optogenetic control of chemokine receptor signal and T-cell migration. Proc Natl Acad Sci U S A. 2014 Apr 29; 111(17):6371-6.
    View in: PubMed
  2. Lim JY, Gerber SA, Murphy SP, Lord EM. Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells. Cancer Immunol Immunother. 2014 Mar; 63(3):259-71.
    View in: PubMed
  3. Majumder S, Sowden MP, Gerber SA, Thomas T, Christie CK, Mohan A, Yin G, Lord EM, Berk BC, Pang J. G-Protein-Coupled Receptor-2-Interacting Protein-1 Is Required for Endothelial Cell Directional Migration and Tumor Angiogenesis via Cortactin-Dependent Lamellipodia Formation. Arterioscler Thromb Vasc Biol. 2014 Feb; 34(2):419-26.
    View in: PubMed
  4. Gerber SA, Lim JY, Connolly KA, Sedlacek AL, Barlow ML, Murphy SP, Egilmez NK, Lord EM. Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors. Int J Cancer. 2014 May 15; 134(10):2383-92.
    View in: PubMed
  5. Sedlacek AL, Gerber SA, Randall TD, van Rooijen N, Frelinger JG, Lord EM. Generation of a dual-functioning antitumor immune response in the peritoneal cavity. Am J Pathol. 2013 Oct; 183(4):1318-28.
    View in: PubMed
  6. Yokota SJ, Facciponte JG, Kelleher RJ, Shultz LD, Loyall JL, Parsons RR, Odunsi K, Frelinger JG, Lord EM, Gerber SA, Balu-Iyer SV, Bankert RB. Changes in ovarian tumor cell number, tumor vasculature, and T cell function monitored in vivo using a novel xenograft model. Cancer Immun. 2013; 13:11.
    View in: PubMed
  7. Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM. IFN-? Mediates the Antitumor Effects of Radiation Therapy in a Murine Colon Tumor. Am J Pathol. 2013 Jun; 182(6):2345-54.
    View in: PubMed
  8. Gerber SA, Sorensen EW, Sedlacek AL, Lim JY, Skrombolas D, Frelinger JG, Lord EM. Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology. 2013 Mar; 138(3):280-92.
    View in: PubMed
  9. Croy BA, Chen Z, Hofmann AP, Lord EM, Sedlacek AL, Gerber SA. Imaging of vascular development in early mouse decidua and its association with leukocytes and trophoblasts. Biol Reprod. 2012 Nov; 87(5):125.
    View in: PubMed
  10. Cummings RJ, Gerber SA, Judge JL, Ryan JL, Pentland AP, Lord EM. Exposure to Ionizing Radiation Induces the Migration of Cutaneous Dendritic Cells by a CCR7-Dependent Mechanism. J Immunol. 2012 Nov 1; 189(9):4247-57.
    View in: PubMed
  11. Valentino MD, Abdul-Alim CS, Maben ZJ, Skrombolas D, Hensley LL, Kawula TH, Dziejman M, Lord EM, Frelinger JA, Frelinger JG. A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens. J Immunol Methods. 2011 Oct 28; 373(1-2):111-26.
    View in: PubMed
  12. Puskas J, Skrombolas D, Sedlacek A, Lord E, Sullivan M, Frelinger J. Development of an attenuated interleukin-2 fusion protein that can be activated by tumour-expressed proteases. Immunology. 2011 Jun; 133(2):206-20.
    View in: PubMed
  13. Sorensen EW, Gerber SA, Frelinger JG, Lord EM. IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms. J Immunol. 2010 Feb 15; 184(4):1858-66.
    View in: PubMed
  14. Cummings RJ, Mitra S, Foster TH, Lord EM. Migration of skin dendritic cells in response to ionizing radiation exposure. Radiat Res. 2009 Jun; 171(6):687-97.
    View in: PubMed
  15. Sorensen EW, Gerber SA, Sedlacek AL, Rybalko VY, Chan WM, Lord EM. Omental immune aggregates and tumor metastasis within the peritoneal cavity. Immunol Res. 2009 Dec; 45(2-3):185-94.
    View in: PubMed
  16. Lord EM. Immunology at the university of Rochester. Immunol Res. 2009 Dec; 45(2-3):97-9.
    View in: PubMed
  17. Cummings RJ, Mitra S, Lord EM, Foster TH. Antibody-labeled fluorescence imaging of dendritic cell populations in vivo. J Biomed Opt. 2008 Jul-Aug; 13(4):044041.
    View in: PubMed
  18. Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008 Mar 1; 180(5):3132-9.
    View in: PubMed
  19. Santos K, Simon DA, Conway E, Bowers WJ, Mitra S, Foster TH, Lugade A, Lord EM, Federoff HJ, Dewhurst S, Frelinger JG. Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors. Hum Gene Ther. 2007 Feb; 18(2):93-105.
    View in: PubMed
  20. Ramanayake T, Simon DA, Frelinger JG, Lord EM, Robert J. In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method. Transplantation. 2007 Jan 27; 83(2):159-66.
    View in: PubMed
  21. Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol. 2006 Nov; 169(5):1739-52.
    View in: PubMed
  22. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005 Jun 15; 174(12):7516-23.
    View in: PubMed
  23. Gerber SA, Turner MJ, Lugade AA, Moran JP, Frelinger JG, Lord EM. Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology. Prostate. 2005 May 1; 63(2):105-16.
    View in: PubMed
  24. Moran JP, Gerber SA, Martin CA, Frelinger JG, Lord EM. Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity. Int J Cancer. 2003 Sep 20; 106(5):690-8.
    View in: PubMed
  25. Gerber SA, Moran JP, Frelinger JG, Frelinger JA, Fenton BM, Lord EM. Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer. 2003 May 6; 88(9):1453-61.
    View in: PubMed
  26. Fisher TL, Nocera M, Willis RA, Turner MJ, Abdul Alim CS, Brown DM, Bourne PA, di Sant'Agnese PA, Messing EM, Lord EM, Frelinger JG. Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors. Prostate. 2002 May 15; 51(3):153-65.
    View in: PubMed
  27. Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG. Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther. 2001 Oct 10; 12(15):1867-79.
    View in: PubMed
  28. Turner MJ, Abdul-Alim CS, Willis RA, Fisher TL, Lord EM, Frelinger JG. T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes. J Immunol Methods. 2001 Oct 1; 256(1-2):107-19.
    View in: PubMed
  29. Fenton BM, Lord EM, Paoni SF. Intravascular HBO(2) saturations, perfusion and hypoxia in spontaneous and transplanted tumor models. Int J Cancer. 2001 Sep 1; 93(5):693-8.
    View in: PubMed
  30. Gerber S, Lane C, Brown DM, Lord E, DiLorenzo M, Clements JD, Rybicki E, Williamson AL, Rose RC. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol. 2001 May; 75(10):4752-60.
    View in: PubMed
  31. Brown DM, Fisher TL, Wei C, Frelinger JG, Lord EM. Tumours can act as adjuvants for humoral immunity. Immunology. 2001 Apr; 102(4):486-97.
    View in: PubMed
  32. Fenton BM, Lord EM, Paoni SF. Effects of radiation on tumor intravascular oxygenation, vascular configuration, development of hypoxia, and clonogenic survival. Radiat Res. 2001 Feb; 155(2):360-8.
    View in: PubMed
  33. Egan RM, Yorkey C, Black R, Loh WK, Stevens JL, Storozynsky E, Lord EM, Frelinger JG, Woodward JG. In vivo behavior of peptide-specific T cells during mucosal tolerance induction: antigen introduced through the mucosa of the conjunctiva elicits prolonged antigen-specific T cell priming followed by anergy. J Immunol. 2000 May 1; 164(9):4543-50.
    View in: PubMed
  34. Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, Stevens C, Weber R, Weinstein G, Benjamin I, Mirza N, Morgan M, Rubin S, McKenna WG, Lord EM, Koch CJ. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res. 2000 Apr 1; 60(7):2018-24.
    View in: PubMed
  35. Lee J, Moran JP, Fenton BM, Koch CJ, Frelinger JG, Keng PC, Lord EM. Alteration of tumour response to radiation by interleukin-2 gene transfer. Br J Cancer. 2000 Feb; 82(4):937-44.
    View in: PubMed
  36. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, Karp JS, Alavi A, Lord EM, Dolbier WR, Koch CJ. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med. 2000 Feb; 41(2):327-36.
    View in: PubMed
  37. Fenton BM, Lord EM, Paoni SF. Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation. Radiat Res. 2000 Jan; 153(1):75-83.
    View in: PubMed
  38. Gee MS, Koch CJ, Evans SM, Jenkins WT, Pletcher CH, Moore JS, Koblish HK, Lee J, Lord EM, Trinchieri G, Lee WM. Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res. 1999 Oct 1; 59(19):4882-9.
    View in: PubMed
  39. Storozynsky E, Woodward JG, Frelinger JG, Lord EM. Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells. Immunology. 1999 May; 97(1):138-49.
    View in: PubMed
  40. Fenton BM, Paoni SF, Lee J, Koch CJ, Lord EM. Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements. Br J Cancer. 1999 Feb; 79(3-4):464-71.
    View in: PubMed
  41. Bergeron M, Evans SM, Sharp FR, Koch CJ, Lord EM, Ferriero DM. Detection of hypoxic cells with the 2-nitroimidazole, EF5, correlates with early redox changes in rat brain after perinatal hypoxia-ischemia. Neuroscience. 1999; 89(4):1357-66.
    View in: PubMed
  42. Clyman RI, Chan CY, Mauray F, Chen YQ, Cox W, Seidner SR, Lord EM, Weiss H, Waleh N, Evans SM, Koch CJ. Permanent anatomic closure of the ductus arteriosus in newborn baboons: the roles of postnatal constriction, hypoxia, and gestation. Pediatr Res. 1999 Jan; 45(1):19-29.
    View in: PubMed
  43. Wei C, Callahan BP, Turner MJ, Willis RA, Lord EM, Barth RK, Frelinger JG. Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes. Int J Mol Med. 1998 Oct; 2(4):487-96.
    View in: PubMed
  44. Yeh KY, McAdam AJ, Pulaski BA, Shastri N, Frelinger JG, Lord EM. IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes. J Immunol. 1998 Jun 15; 160(12):5773-80.
    View in: PubMed
  45. Lord EM, Yeh KY, Moran JA, Storozynsky E, Frelinger JG. IL-3-mediated enhancement of particulate antigen presentation by macrophages. J Immunother. 1998 May; 21(3):205-10.
    View in: PubMed
  46. Lord EM, Frelinger JG. Tumor immunotherapy: cytokines and antigen presentation. Cancer Immunol Immunother. 1998 Apr; 46(2):75-81.
    View in: PubMed
  47. Lee J, Fenton BM, Koch CJ, Frelinger JG, Lord EM. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment. Cancer Res. 1998 Apr 1; 58(7):1478-85.
    View in: PubMed
  48. Willis RA, Wei C, Turner MJ, Callahan BP, Pugh AE, Barth RK, Lord EM, Frelinger JG. A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review). Int J Mol Med. 1998 Feb; 1(2):379-86.
    View in: PubMed
  49. Fenton BM, Paoni SF, Koch CJ, Lord EM. Effect of local irradiation on tumor oxygenation, perfused vessel density, and development of hypoxia. Adv Exp Med Biol. 1998; 454:619-28.
    View in: PubMed
  50. Yeh KY, Chen Z, Nasir A, Ohsuga Y, Takashima A, Lord EM, Gaspari AA. Expression of B7-1 by Pam 212 squamous cell carcinoma enhances tumor cell interactions with dendritic epidermal cells but does not affect in vivo tumor growth. J Invest Dermatol. 1997 Dec; 109(6):728-33.
    View in: PubMed
  51. Bialik S, Geenen DL, Sasson IE, Cheng R, Horner JW, Evans SM, Lord EM, Koch CJ, Kitsis RN. Myocyte apoptosis during acute myocardial infarction in the mouse localizes to hypoxic regions but occurs independently of p53. J Clin Invest. 1997 Sep 15; 100(6):1363-72.
    View in: PubMed
  52. Nozue M, Lee I, Yuan F, Teicher BA, Brizel DM, Dewhirst MW, Milross CG, Milas L, Song CW, Thomas CD, Guichard M, Evans SM, Koch CJ, Lord EM, Jain RK, Suit HD. Interlaboratory variation in oxygen tension measurement by Eppendorf "Histograph" and comparison with hypoxic marker. J Surg Oncol. 1997 Sep; 66(1):30-8.
    View in: PubMed
  53. Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. Proc Natl Acad Sci U S A. 1997 Jun 10; 94(12):6369-74.
    View in: PubMed
  54. Shapiro IM, Mansfield KD, Evans SM, Lord EM, Koch CJ. Chondrocytes in the endochondral growth cartilage are not hypoxic. Am J Physiol. 1997 Apr; 272(4 Pt 1):C1134-43.
    View in: PubMed
  55. Evans SM, Bergeron M, Ferriero DM, Sharp FR, Hermeking H, Kitsis RN, Geenen DL, Bialik S, Lord EM, Koch CJ. Imaging hypoxia in diseased tissues. Adv Exp Med Biol. 1997; 428:595-603.
    View in: PubMed
  56. Koch CJ, Lord EM, Shapiro IM, Clyman RI, Evans SM. Imaging hypoxia and blood flow in normal tissues. Adv Exp Med Biol. 1997; 428:585-93.
    View in: PubMed
  57. Lee J, Siemann DW, Koch CJ, Lord EM. Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts. Int J Cancer. 1996 Jul 29; 67(3):372-8.
    View in: PubMed
  58. Wei C, Storozynsky E, McAdam AJ, Yeh KY, Tilton BR, Willis RA, Barth RK, Looney RJ, Lord EM, Frelinger JG. Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 1996 Jul; 42(6):362-8.
    View in: PubMed
  59. Matthews J, Adomat H, Farrell N, King P, Koch C, Lord E, Palcic B, Poulin N, Sangulin J, Skov K. Immunocytochemical labelling of aerobic and hypoxic mammalian cells using a platinated derivative of EF5. Br J Cancer Suppl. 1996 Jul; 27:S200-3.
    View in: PubMed
  60. Laughlin KM, Evans SM, Jenkins WT, Tracy M, Chan CY, Lord EM, Koch CJ. Biodistribution of the nitroimidazole EF5 (2-[2-nitro-1H-imidazol-1-yl]-N-(2,2,3,3,3-pentafluoropropyl) acetamide) in mice bearing subcutaneous EMT6 tumors. J Pharmacol Exp Ther. 1996 May; 277(2):1049-57.
    View in: PubMed
  61. Pulaski BA, Yeh KY, Shastri N, Maltby KM, Penney DP, Lord EM, Frelinger JG. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells. Proc Natl Acad Sci U S A. 1996 Apr 16; 93(8):3669-74.
    View in: PubMed
  62. Evans SM, Jenkins WT, Joiner B, Lord EM, Koch CJ. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors. Cancer Res. 1996 Jan 15; 56(2):405-11.
    View in: PubMed
  63. Woods ML, Koch CJ, Lord EM. Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies. Int J Radiat Oncol Biol Phys. 1996 Jan 1; 34(1):93-101.
    View in: PubMed
  64. Waleh NS, Brody MD, Knapp MA, Mendonca HL, Lord EM, Koch CJ, Laderoute KR, Sutherland RM. Mapping of the vascular endothelial growth factor-producing hypoxic cells in multicellular tumor spheroids using a hypoxia-specific marker. Cancer Res. 1995 Dec 15; 55(24):6222-6.
    View in: PubMed
  65. Yeh KY, Pulaski BA, Woods ML, McAdam AJ, Gaspari AA, Frelinger JG, Lord EM. B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma. Cell Immunol. 1995 Oct 15; 165(2):217-24.
    View in: PubMed
  66. McAdam AJ, Pulaski BA, Storozynsky E, Yeh KY, Sickel JZ, Frelinger JG, Lord EM. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell Immunol. 1995 Oct 15; 165(2):183-92.
    View in: PubMed
  67. Evans SM, Joiner B, Jenkins WT, Laughlin KM, Lord EM, Koch CJ. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer. 1995 Oct; 72(4):875-82.
    View in: PubMed
  68. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. Br J Cancer. 1995 Oct; 72(4):869-74.
    View in: PubMed
  69. McAdam AJ, Pulaski BA, Harkins SS, Hutter EK, Lord EM, Frelinger JG. Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells. Int J Cancer. 1995 May 29; 61(5):628-34.
    View in: PubMed
  70. Koch CJ, Evans SM, Lord EM. Comment on the hypothesis that hyperthermia facilitates reoxygenation. Int J Hyperthermia. 1995 May-Jun; 11(3):447-50.
    View in: PubMed
  71. Wan XS, Koch CJ, Lord EM, Manzone H, Billings PC, Donahue JJ, Odell CS, Miller JH, Schmidt NA, Kennedy AR. Monoclonal antibodies differentially reactive with native and reductively modified Bowman-Birk protease inhibitor. J Immunol Methods. 1995 Mar 13; 180(1):117-30.
    View in: PubMed
  72. McAdam AJ, Felcher A, Woods ML, Pulaski BA, Hutter EK, Frelinger JG, Lord EM. Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes. J Immunother Emphasis Tumor Immunol. 1994 Apr; 15(3):155-64.
    View in: PubMed
  73. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res. 1993 Dec 1; 53(23):5721-6.
    View in: PubMed
  74. Woods ML, McAdam AJ, Frelinger JG, Lord EM. Isolation and expansion of tumor-infiltrating lymphocytes. Biotechniques. 1993 Dec; 15(6):970-2.
    View in: PubMed
  75. McAdam AJ, Yeh KY, Pulaski BA, Frelinger JG, Lord EM. Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2. J Immunother Emphasis Tumor Immunol. 1993 Nov; 14(4):293-7.
    View in: PubMed
  76. Chen Z, Rosten SI, Lord EM, Gaspari AA. Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms. Reg Immunol. 1993 Sep-Oct; 5(5):285-92.
    View in: PubMed
  77. McAdam A, Pulaski B, Harkins S, Hutter E, Frelinger J, Lord E. Coexpression of IL-2 and gamma-IFN enhances tumor immunity. Ann N Y Acad Sci. 1993 Aug 12; 690:349-51.
    View in: PubMed
  78. Lord E, McAdam A, Felcher A, Woods M, Pulaski B, Hutter E, Frelinger J. Transfection of TGF-beta producing tumors with IL-2 elicits tumor rejection. Ann N Y Acad Sci. 1993 Aug 12; 690:346-8.
    View in: PubMed
  79. Pulaski BA, McAdam AJ, Hutter EK, Biggar S, Lord EM, Frelinger JG. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res. 1993 May 1; 53(9):2112-7.
    View in: PubMed
  80. McAdam AJ, Blieden TM, Frelinger JG, Lord EM. CD4-class II major histocompatibility complex interaction does not enhance killing by a class I-restricted CD4+CD8+ cytotoxic T cell clone. Eur J Immunol. 1992 Sep; 22(9):2461-4.
    View in: PubMed
  81. Cerosaletti KM, Woodward JG, Lord EM, Frelinger JG. Two regions of the H-2 Dd promoter are responsive to dimethylsulfoxide in line 1 cells by a mechanism distinct from IFN-gamma. J Immunol. 1992 Feb 15; 148(4):1212-21.
    View in: PubMed
  82. Blieden TM, McAdam AJ, Frelinger JG, Lord EM. Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor. J Immunol. 1991 Aug 15; 147(4):1433-8.
    View in: PubMed
  83. Blieden TM, McAdam AJ, Foresman MD, Cerosaletti KM, Frelinger JG, Lord EM. Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors. Int J Cancer Suppl. 1991; 6:82-9.
    View in: PubMed
  84. Cerosaletti KM, Blieden TM, Harwell LW, Welsh KM, Frelinger JG, Lord EM. Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection. Cell Immunol. 1990 May; 127(2):299-310.
    View in: PubMed
  85. Loeffler DA, Keng PC, Baggs RB, Lord EM. Lymphocytic infiltration and cytotoxicity under hypoxic conditions in the EMT6 mouse mammary tumor. Int J Cancer. 1990 Mar 15; 45(3):462-7.
    View in: PubMed
  86. Wilson KM, Siegal G, Lord EM. Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages. Cell Immunol. 1989 Oct 1; 123(1):158-65.
    View in: PubMed
  87. Liu YC, Marraccino RL, Keng PC, Bambara RA, Lord EM, Chou WG, Zain SB. Requirement for proliferating cell nuclear antigen expression during stages of the Chinese hamster ovary cell cycle. Biochemistry. 1989 Apr 4; 28(7):2967-74.
    View in: PubMed
  88. Bahler DW, Cerosaletti KM, Lord EM, Frelinger JG. Molecular analysis of deficient class I H-2 antigen expression by mouse lung carcinoma cells. J Immunol. 1988 Jun 1; 140(11):4003-12.
    View in: PubMed
  89. Dennert G, Landon C, Lord EM, Bahler DW, Frelinger JG. Lysis of a lung carcinoma by poly I:C-induced natural killer cells is independent of the expression of class I histocompatibility antigens. J Immunol. 1988 Apr 1; 140(7):2472-5.
    View in: PubMed
  90. Marraccino RL, Wahl AF, Keng PC, Lord EM, Bambara RA. Cell cycle dependent activities of DNA polymerases alpha and delta in Chinese hamster ovary cells. Biochemistry. 1987 Dec 1; 26(24):7864-70.
    View in: PubMed
  91. Loeffler DA, Keng PC, Wilson KM, Lord EM. Comparison of fluorescence intensity of Hoechst 33342-stained EMT6 tumour cells and tumour-infiltrating host cells. Br J Cancer. 1987 Nov; 56(5):571-6.
    View in: PubMed
  92. Bahler DW, Frelinger JG, Harwell LW, Lord EM. Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection. Proc Natl Acad Sci U S A. 1987 Jul; 84(13):4562-6.
    View in: PubMed
  93. Wilson KM, Lord EM. Specific (EMT6) and non-specific (WEHI-164) cytolytic activity by host cells infiltrating tumour spheroids. Br J Cancer. 1987 Feb; 55(2):141-6.
    View in: PubMed
  94. Wahl AF, Crute JJ, Sabatino RD, Bodner JB, Marraccino RL, Harwell LW, Lord EM, Bambara RA. Properties of two forms of DNA polymerase delta from calf thymus. Biochemistry. 1986 Dec 2; 25(24):7821-7.
    View in: PubMed
  95. Knauf S, Kalwas J, Helmkamp BF, Harwell LW, Beecham J, Lord EM. Monoclonal antibodies against human ovarian tumor associated antigen NB/70K: preparation and use in a radioimmunoassay for measuring NB/70K in serum. Cancer Immunol Immunother. 1986; 21(3):217-25.
    View in: PubMed
  96. Wilson KM, Lord EM. Effects of radiation on host-tumor interactions using the multicellular tumor spheroid model. Cancer Immunol Immunother. 1986; 23(1):20-4.
    View in: PubMed
  97. Bahler DW, Lord EM. Enhanced immune recognition of H-2 antigen-deficient murine lung carcinoma cells following treatment with dimethyl sulfoxide. Cancer Res. 1985 Dec; 45(12 Pt 1):6362-5.
    View in: PubMed
  98. Bahler DW, Lord EM. Dimethyl sulfoxide induces expression of H-2 antigens on mouse lung carcinoma cells. J Immunol. 1985 Apr; 134(4):2790-8.
    View in: PubMed
  99. Bahler DW, Lord EM, Kennel SJ, Horan PK. Heterogeneity and clonal variation related to cell surface expression of a mouse lung tumor-associated antigen quantified using flow cytometry. Cancer Res. 1984 Aug; 44(8):3317-23.
    View in: PubMed
  100. Lord EM, Burkhardt G. Assessment of in situ host immunity to syngeneic tumors utilizing the multicellular spheroid model. Cell Immunol. 1984 May; 85(2):340-50.
    View in: PubMed
  101. Wahl AF, Kowalski SP, Harwell LW, Lord EM, Bambara RA. Immunoaffinity purification and properties of a high molecular weight calf thymus DNA alpha-polymerase. Biochemistry. 1984 Apr 24; 23(9):1895-9.
    View in: PubMed
  102. Lord EM, Keng PC. Methods for using centrifugal elutriation to separate malignant and lymphoid cell populations. J Immunol Methods. 1984 Mar 30; 68(1-2):147-55.
    View in: PubMed
  103. Harwell LW, Bolognino M, Bidlack JM, Knapp RJ, Lord EM. A freezing method for cell fusions to distribute and reduce labor and permit more thorough early evaluation of hybridomas. J Immunol Methods. 1984 Jan 20; 66(1):59-67.
    View in: PubMed
  104. Landry JM, Lord EM, Sutherland RM. In vivo growth of tumor cell spheroids after in vitro hyperthermia. Cancer Res. 1982 Jan; 42(1):93-9.
    View in: PubMed
  105. Greenstein JL, Lord E, Kappler JW, Marrack PC. Analysis of the response of B cells from CBA/N-defective mice to nonspecific T cell help. J Exp Med. 1981 Nov 1; 154(5):1608-17.
    View in: PubMed
  106. Keng PC, Wheeler KT, Siemann DW, Lord EM. Direct synchronization of cells from solid tumors by centrifugal elutriation. Exp Cell Res. 1981 Jul; 134(1):15-22.
    View in: PubMed
  107. Siemann DW, Lord EM, Keng PC, Wheeler KT. Cell subpopulations dispersed from solid tumours and separated by centrifugal elutriation. Br J Cancer. 1981 Jul; 44(1):100-8.
    View in: PubMed
  108. Greenstein JL, Lord EM, Horan P, Kappler JW, Marrack P. Functional subsets of B cells defined by quantitative differences in surface I-A. J Immunol. 1981 Jun; 126(6):2419-23.
    View in: PubMed
  109. Lord EM, Nardella GB, Sutherland RM. The multicellular tumor spheroid model. I. Characterization of the allograft response in sensitized mice. Cell Immunol. 1980 Jun; 52(1):119-31.
    View in: PubMed
  110. Lord EM. Comparison of in situ and peripheral host immunity to syngeneic tumours employing the multicellular spheroid model. Br J Cancer Suppl. 1980 Apr; 4:123-7.
    View in: PubMed
  111. Lord EM, Nardella G. The multicellular tumor spheroid model. II. Characterization of the primary allograft response in unsensitized mice. Transplantation. 1980 Feb; 29(2):119-24.
    View in: PubMed
  112. Lord EM, Penney DP, Sutherland RM, Cooper RA. Morphological and functional characteristics of cells infiltrating and destroying tumor multicellular spheroids in vivo. Virchows Arch B Cell Pathol Incl Mol Pathol. 1979 Oct; 31(2):103-16.
    View in: PubMed
  113. Schmidt L, Erickson RP, Lord E, Stites DP. Murine anti-spermatozoal antibodies induced by sperm-tetanus toxoid conjugates. Biol Reprod. 1977 Sep; 17(2):207-12.
    View in: PubMed
  114. Lord EM, Sensabaugh GF, Stites DP. Immunosuppressive activity of human seminal plasma. I. Inhibition of in vitro lymphocyte activation. J Immunol. 1977 May; 118(5):1704-11.
    View in: PubMed
  115. Lord EM, Dutton RW. Antigen suppression of the in vitro development of plaque-forming cells to autologous erythrocyte antigens. J Immunol. 1975 Dec; 115(6):1631-5.
    View in: PubMed
  116. Lord EM, Dutton RW. The properties of plaque-forming cells from autoimmune and normal strains of mice with specificity for autologous erythrocyte antigens. J Immunol. 1975 Nov; 115(5):1199-1205.
    View in: PubMed
  117. Kappler JW, Hunter PC, Jacobs D, Lord E. Functional heterogeneity among the T-derived lymphocytes of the mouse. I. Analysis by adult thymectomy. J Immunol. 1974 Jul; 113(1):27-38.
    View in: PubMed
  118. Sher A, Lord E, Cohn M. Reconstitution from subunits of the hapten binding sites and idiotypic determinants of mouse anti-phosphorylcholine myeloma proteins. J Immunol. 1971 Nov; 107(5):1226-34.
    View in: PubMed

Visualizations


Lord's Networks

Concepts
_
Co-Authors
_
Similar People
_
Same Department